Tier 2 — strong

The acute effect of different NAD + precursors included in the combined metabolic activators

Li X, Yang H, Jin H, Turkez H, Ozturk G, Doganay HL, Zhang C, Nielsen J, Uhlén M, Borén J, Mardinoglu A
Free radical biology & medicine 2023 205; 77-89

Bibliography

PubMed
PMID 37271226
DOI
10.1016/j.freeradbiomed.2023.05.032
Funding
Funding details are not specified in the accessible publication information.
Competing interests
Disclosures include consultancy and founder/shareholder relationships with Bash Biotech.

Study snapshot

DesignHuman pharmacokinetic study
ModelHuman participants
SampleHealthy human participants across six combination formulations
InterventionCombination metabolic activators with 1 g of different NAD+ precursors
DurationOne-day acute study
EndpointsAcute plasma metabolome; tolerability

What the study showed, in plain terms

The formulations produced distinct plasma metabolomic responses, illustrating that NAD+ precursors can behave differently within a multi-ingredient mixture.

Key findings

The formulations produced distinct plasma metabolomic responses, illustrating that NAD+ precursors can behave differently within a multi-ingredient mixture.

What this study can and cannot tell us

Acute metabolomics, rather than disease outcomes. These combinations do not establish clinical superiority of one precursor or effects of NR alone.

Related papers in the corpus

Tier 2
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial
Yulug B et al. · Brain communications · 2025
Tier 2
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Yulug B et al. · Translational neurodegeneration · 2023
Tier 2
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
Altay O et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
Tier 2
Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
Zeybel M et al. · Molecular systems biology · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology